Milking the sevelamer-calcium debate  by Chertow, Glenn M. & Raggi, Paolo A.
Letters to the Editor 2329
Sevelamer: Where are
the data?
To the Editor: In their study of sevelamer versus
calcium-based phosphate binders in hemodialysis pa-
tients, Chertow et al [1], in a recent issue of Kidney In-
ternational concluded that sevelamer attenuates vascular
calcifications while maintaining good phosphorus con-
trol. The implications of this claim are exemplified by
the aggressive marketing efforts of this study’s sponsor,
Genzyme Corporation [2].
Canavese et al [3] raised critical statistical issues re-
garding the study in their subsequent letter to Kidney
International. They noted that “the patients cited in
Tables 3 and 4 . . . are not the same,” and that “multivari-
ate analysis of the role of hypercalcemia and hypercal-
cemic episodes in the progression of calcification” was
not provided. Neither point was addressed in the authors’
reply [4].
The means and standard deviations of baseline electron
beam tomography (EBT) scores (Table 3) document that
score distributions were not comparable between groups.
Furthermore, ∼30% of the baseline cohort was excluded
from the 26- and 52-week analyses. Without baseline dis-
tribution of EBT scores for the actual population ana-
lyzed, absolute or percentage changes cannot be deter-
mined. Further weakening the validity of this study’s find-
ings are the absence of evidence of the reproducibility of
the EBT measurements and the failure to make appro-
priate statistical adjustments for subjects who dropped
out of the study (Table 3, footnote). Those adjustments
may reveal that even the primary end point, phosphorus
control, was not achieved.
With provision of the data requested here and by
Canavese, reanalysis may likely determine that there
were no differences between absolute EBT scores of the
two groups or in the changes in the 52-week EBT scores.
Until these additional data are published in a transpar-
ent fashion, the authors’ claim that sevelamer attenuates
cardiovascular calcification remains purely speculative.
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Milking the sevelamer-calcium debate
We are delighted that the results of our randomized
clinical trial comparing calcium-based phosphate binders
with sevelamer [1] continue to be of interest to readers
of Kidney International, prompting Letters to the Editor
more than one year after the publication date. It is es-
pecially gratifying to read such a letter from Professor
McCarron, a leading researcher who has published more
than 200 articles over the past 20 years, including more
than 150 on the topic of calcium.
Professor McCarron correctly summarized our conclu-
sion, that relative to calcium salts, sevelamer attenuated
the progression of coronary artery and aortic calcifica-
tion, and indeed, sevelamer (and calcium) provided good
control of serum phosphorus. Our initial reply to four let-
ters to the Editor was necessarily brief; the major issues
raised by Canavese et al [2] and other authors were ad-
dressed [3]. Herein we provide additional requested data.
If one were to consider only those 150 study subjects
who underwent a follow-up electron beam tomography
(EBT) scan, the baseline median (interquartile range)
coronary artery calcium scores were 665 (79 to 2250) and
578 (76 to 1294) in the sevelamer- and calcium-treated
subjects, respectively (P = 0.30). Corresponding median
(interquartile range) aortic calcium scores were 668 (25
to 3662) and 360 (4 to 4030) (P = 0.61). These results are
similar to the results for all study subjects who underwent
baseline EBT scanning (N = 186) reported in Table 3.
Among calcium-treated subjects, the changes in
coronary artery and aortic calcification were directly
correlated with the time-averaged serum calcium concen-
tration (r = 0.18 and r = 0.28, respectively). The median
changes in calcification were significantly higher when
the time-averaged serum calcium concentrations were
greater than or equal to 9.5 mg/dL.
Professor McCarron claims that the validity of the
study is weakened by the “absence of evidence of re-
producibility of the EBT measurements.” Indeed, in the
manuscript we stated “the median inter-scan variability
is 8% to 10% for the Agatston score” and we provided
supporting references. Professor McCarron also contends
that we failed to “make appropriate statistical adjust-
ments for subjects who dropped out of the study” and
that “those adjustments may reveal that even the primary
endpoint, phosphorus control, was not achieved.” In the
manuscript we stated that “all laboratory analyses were
performed using a last value carried forward approach,” a
conservative method commonly used to account for the
analysis of continuous variables in a longitudinal study
2330 Letters to the Editor
[4]. Considering only measured serum phosphorus con-
centrations in the 150 subjects with repeat EBT, the time-
averaged serum phosphorus concentrations were 5.3 ±
0.9 and 5.4 ± 1.0 mg/dL in the sevelamer- and calcium-
treated groups, respectively (P = 0.94).
One wonders why Professor McCarron believes that
“reanalysis may likely determine that there were no dif-
ferences between absolute EBT scores of the two groups
or in the changes in the 52-week EBT scores.” These were
precisely the analyses provided in [1], in as “transparent”
a fashion as possible. Indeed, we specifically stated that
“evaluation of the change in calcification was performed
in several ways owing to imperfections of each approach”
and that “we resolved to report absolute and relative ef-
fects . . . recognizing that qualitatively and quantitatively
consistent results would be required for our conclusions
to be robust.” Could we have been any more transparent?
We were interested to learn of Professor McCarron’s
involvement with certain organizations whose interests
might be furthered by trumpeting the benefits of calcium.
According to the Center for Science in the Public Inter-
est (CSPI) [5], Professor McCarron has served as Direc-
tor of the Calcium Information Center, a joint project of
Oregon Health Sciences Center, New York Hospital-
Cornell Medical Center, and Memorial Sloan Kettering
Cancer Center. The Calcium Information Center was
funded in part by SmithKline Beecham, the maker of
Tums brand of calcium carbonate. CSPI also notes that
Professor McCarron has received numerous grants from
the National Dairy Council. A brief on-line tour reveals
other industrial contacts, including Cole Bros. [6], a bot-
tler of calcium-rich mineral water (sporting the highest
calcium content of 15 brands shown). In addition to his
role as Visiting Professor in the Department of Nutrition
at University of California Davis (per the signature below
the Letter to the Editor), Professor McCarron serves as
President of Academic Network LLC, a healthcare
telecommunications service bureau and consulting firm
located in Portland, OR [7]. Academic Network, LLC
counts among its clients Cole Bros., Dairy Management,
Inc., and the International Dairy Foods Association.
Kathleen A. McCarron is Chief Executive Officer of
Academic Network, LLC.
While we welcome criticism of our work, we respect-
fully request that the pages of Kidney International, a
prestigious journal on which we depend for accurate
information, be used as a forum for the advancement
of science, rather than as a battleground for industrial
interests.
Disclosure: Drs. Chertow and Raggi have received re-
search funds from, and have served on an advisory board
with Genzyme, Inc. Neither Dr. Chertow nor Dr. Raggi
own stock in or have any other financial interest in Gen-
zyme, Inc. Steven K. Burke, M.D., a coauthor of the study
to which this letter was addressed, is an employee of Gen-
zyme, Inc., and did not contribute to this Reply.
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